Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Accumulated Expenses data on file, last reported at $594900.0 in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $594900.0, down 85.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $594900.0 (down 85.0% YoY), and the FY2025 annual result was $535500.0, down 91.31% from the prior year.
• Accumulated Expenses climbed to $594900.0 in Q1 2026 per RLMD's latest filing, from $535500.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.4 million in Q2 2022 and troughed at $73200.0 in Q2 2023.
• A 5-year average of $4.8 million and a median of $5.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 14797.21% in 2022, then tumbled 99.36% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $7.2 million in 2022, then rose by 20.56% to $8.7 million in 2023, then retreated by 29.09% to $6.2 million in 2024, then slumped by 91.31% to $535500.0 in 2025, then climbed by 11.09% to $594900.0 in 2026.
• Business Quant data shows RLMD's Accumulated Expenses at $594900.0 in Q1 2026, $535500.0 in Q4 2025, and $532600.0 in Q3 2025.